View source for 18331004. NOVEL PEPTIDES CAPABLE OF ALTERING NK CELL ACTIVITY simplified abstract (Massachusetts Institute of Technology)

=NOVEL PEPTIDES CAPABLE OF ALTERING NK CELL ACTIVITY=


==Organization Name==

[[:Category:Massachusetts Institute of Technology|Massachusetts Institute of Technology]]


[[Category:Massachusetts Institute of Technology]]

==Inventor(s)==

[[:Category:Michael Birnbaum of Arlington MA (US)|Michael Birnbaum of Arlington MA (US)]][[Category:Michael Birnbaum of Arlington MA (US)]]

[[:Category:Brooke Huisman of Clarkston MI (US)|Brooke Huisman of Clarkston MI (US)]][[Category:Brooke Huisman of Clarkston MI (US)]]

[[:Category:Chiara Romagnani of Berlin (DE)|Chiara Romagnani of Berlin (DE)]][[Category:Chiara Romagnani of Berlin (DE)]]

[[:Category:Timo R�ckert of Berlin (DE)|Timo R�ckert of Berlin (DE)]][[Category:Timo R�ckert of Berlin (DE)]]

==NOVEL PEPTIDES CAPABLE OF ALTERING NK CELL ACTIVITY - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18331004 titled 'NOVEL PEPTIDES CAPABLE OF ALTERING NK CELL ACTIVITY

==Simplified Explanation==

The patent application provides peptides that bind to HLA-E and modulate immune cell activity, selectively activating NKG2C+ cells and inhibiting NKG2A+ cells.

* Peptides bind to HLA-E
* Activate NKG2C+ immune cells
* Inhibit NKG2A+ cells
* Treat autoimmune diseases, infectious diseases, and cancer

== Potential Applications ==
The technology can be applied in the following areas:
* Treatment of autoimmune diseases
* Treatment of infectious diseases
* Treatment of cancer

== Problems Solved ==
The technology addresses the following issues:
* Overactive immune responses
* Lack of targeted immune cell activation
* Limited treatment options for certain diseases

== Benefits ==
The technology offers the following benefits:
* Selective immune cell activation
* Potential for personalized medicine
* Improved treatment outcomes

== Potential Commercial Applications ==
The technology can be utilized in various commercial applications, such as:
* Pharmaceutical industry
* Biotechnology companies
* Immunotherapy research

== Possible Prior Art ==
Prior art may include:
* Peptide-based therapies targeting immune cells
* HLA-E binding peptides in immunotherapy research

== Unanswered Questions ==
1. How specific are the peptides in targeting NKG2C+ and NKG2A+ cells?
2. What are the potential side effects of modulating immune cell activity with these peptides?


==Original Abstract Submitted==

Peptides capable of binding to HLA-E and affecting immune cell activity are provided. Such peptides can selectively activate NKG2C+ immune cells such as natural killer (NK) cells and/or can inhibit NKG2A+ cells to decrease or suppress immune cell responses. Methods of use of the peptides are also disclosed, for instance, for treating or inhibiting the development or progression of a multitude of illnesses and conditions, including autoimmune disease, infectious disease such as viral or bacterial infection, and proliferative disorders such as cancer.



[[Category:C07K7/06]]
[[Category:A61P37/04]]